Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

Summary

Abiraterone acetate is an orally effective CYP17 inhibitor, which is metabolized into abiraterone in the body, and its inhibitory activity against CYP17 is 10-30 times that of ketoconazole. Clinical studies have shown that abiraterone acetate can significantly reduce the level of prostate specific antigen (PSA) in PCa patients, and help to reduce tumors, extending the lifespan of patients with advanced PCa for several years, and the toxicity is acceptable.

Timeline

Start

2014-07-16

Primary completion

2018-03-14

Completion

2019-07-16

Drugs

Indications